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INTEGRATE-Vis: a tool for 
comprehensive gene fusion 
visualization
Jin Zhang1, Teng Gao2,5 & Christopher A. Maher2,3,4,6
Despite the increasing quantity of tools for accurately predicting gene fusion candidates from 
sequencing data, we are still faced with the critical challenge of visualizing the corresponding gene 
fusion products to infer their biological consequence (i.e. novel protein and increased gene expression). 
This is currently accomplished by manually inspecting and inferring the biological consequence of 
top scoring gene fusion candidates. This labor-intensive process could be made easier by automating 
the annotation of gene fusion products and generating easily interpretable visualizations. We 
developed a gene fusion visualization tool, called INTEGRATE-Vis, that generates comprehensive, 
highly customizable, publication-quality graphics focused on annotating each gene fusion at the 
transcript- and protein-level and assessing expression within an individual sample or across a patient 
cohort. INTEGRATE-Vis is the first comprehensive gene fusion visualization tool to help a user infer 
the potential consequence of a gene fusion event. It has potential utility in both research and clinical 
settings. INTEGRATE-Vis is available at https://github.com/ChrisMaherLab/INTEGRATE-Vis.
Gene fusions have served as highly specific diagnostic markers, prognostic indicators and therapeutic targets1. 
High throughput transcriptome sequencing (RNA-Seq) has accelerated our ability to discover expressed gene 
fusions2. While recent tools, such as INTEGRATE3, are highly sensitive and specific, we are still faced with 
the critical challenge of ensuring that a casual gene fusion is not only detected, but that it can be prioritized 
accordingly amongst passenger events. This is currently accomplished by manually inspecting and inferring the 
biological consequence (i.e., generation of a novel protein, altered expression levels) of top scoring gene fusion 
candidates. The labor-intensive process could be made easier and more precise by automating the annotation 
of gene fusion transcripts and proteins and generating easily interpretable visualizations. Currently gene fusion 
visualization approaches either rely on CIRCOS to highlight the genomic locations of the gene fusion partners4, 
IGV for assessing sequence coverage at fusion junctions5, or splicing graphs to observe the exons involved in 
a gene fusion6. Individually each of these methods is insufficient for inferring the consequences of the gene 
fusion on expression or the corresponding protein product. To address these limitations, we developed a tool, 
INTEGRATE-Vis, which generates multiple visualizations for annotating each gene fusion, at the transcript- and 
protein-level, and assessing gene expression within an individual sample or across a cohort.
Results
INTEGRATE-Vis pipeline (Fig. 1) generates four types of figures, created manually in previous publications, to 
provide easy-to-interpret visualizations of gene fusion predictions3,7–10. To illustrate how INTEGRATE-Vis works 
we focused on a prostate cancer patient harboring the most prevalent gene fusion, TMPRSS2-ERG, that results in 
the marked increase in the expression of the oncogenic transcription factor ERG (Fig. 2). Panels A through D of 
Fig. 2 correspond to structure plot, domain plot, exon expression plot, and gene expression plot outputs described 
in Fig. 1, respectively.
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Figure 1. Overview of the INTEGRATE-Vis pipeline. INTEGRATE-Vis contains four major modules to plot 
four types of figures for gene fusions: isoform structure, domain, exon expression, and gene partner expression. 
The first three modules are for individual samples, and the last module is for cohort data. Only minimal inputs 
in standard formats, including BEDPE, TSV, FASTA, BAM, and GTF are needed to make the plots.
Figure 2. INTEGRATE-Vis output illustrated using the TMPRSS2-ERG gene fusion in prostate cancer. 
INTEGRATE-Vis outputs four visualizations including: (A) gene fusion transcript isoforms, (B) the predicted 
protein structure of the gene fusion, (C) RNA-Seq read coverage across each gene fusion partner to reveal 
changes in exon expression (A red line is plotted at the fusion junctions at both gene partners. Exon boundaries 
are represented by blue lines. A marked expression change occurs between exons 3 and 4 of ERG.), and (D) 
expression of each gene fusion partner across the TCGA PRAD cohort. Blue is used to represent supporting 
reads, exons, transcript, and genomic locations for the 5′ gene partner (TMPRSS2), while red is for those of the 
3′ gene partner (ERG).
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First, in our structure plot we show the predicted gene fusion transcript structure highlighting sequence reads 
that encompass and span the fusion junction (Fig. 2A). Both TMPRSS2 and ERG are on the reverse strand of chro-
mosome 22 in two consecutive cytogenetic bands. A genomic deletion between the upstream gene, TMPRSS2, 
and the downstream partner, ERG, generates the gene fusion event. By default, INTEGRATE-Vis constructs a 
gene fusion transcript isoform using the most prevalent transcript isoform of the gene partners. Alternatively, a 
user can designate specific transcript isoforms to display in the reconstructed gene fusion transcript. As shown 
in Fig. 2A, a 14-exon isoform (ENST00000458356) of TMPRSS2 and a 12-exon isoform (ENST00000398919) of 
ERG were used for visualization. The fusion junction is located at the second exon of ENST00000458356 and the 
fourth exon of ENST00000398919. The gene fusion transcript is shown in the upper panel with the corresponding 
supporting reads to infer the expression level. To conserve space, INTEGRATE-Vis displays 1, 2, or 3 supporting 
reads to illustrate 1, 2–10, or >10 supporting sequence reads, respectively.
Second, to predict the potential functional consequences of a gene fusion INTEGRATE-Vis generates a 
domain plot to translate the fusion transcript and displays the corresponding protein domains (Fig. 2B). The 
protein product from the 5′ gene partner (i.e. TMPRSS2) is plotted on the left and the protein product from the 
3′ gene partner (i.e. ERG) is plotted on the right. This is also indicated by the annotation of N and C for N- and 
C- terminuses (Fig. 2B). As shown in Fig. 2B, the in-frame gene fusion protein product is comprised of a small 5′ 
regulatory region of TMPRSS2 and the majority of ERG. This includes both the ETS domain and Pointed domain 
of the ERG gene. As shown in Figure S1, for out-of-frame gene fusion transcripts, the 3′ end is represented by a 
white box and a red cross is used to represent the translation termination site.
Third, to determine whether the gene fusion increases the expression of the 3′ partner (i.e., oncogene) or 
decreases the expression of the 5′ partner (i.e., tumor suppressor), INTEGRATE-Vis generates an exon expres-
sion plot. This displays read coverage for the exon-level expression for each gene involved in the fusion (Fig. 2C). 
As shown in Fig. 2C, the ERG exons involved in the gene fusion (exons 4 through 12) have significantly higher 
read coverage compared to the exons that are not included in the gene fusion (exons 1 through 3). Notably, 
INTEGRATE-Vis automatically selects the scales for the y- and x-axes to show the ranges of read coverage for 
each gene partner, although they can be adjusted based on user-defined input (Figure S2).
Fourth, to determine if the sample harboring the gene fusion results in a unique expression change relative 
to a cohort of samples (e.g., prostate cancer patients lacking the gene fusion), INTEGRATE-Vis generates a gene 
expression plot. This outputs a bar plot of the expression level for both genes involved in the fusion across a 
patient cohort (Fig. 2D). For example, Fig. 2D highlights the difference in ERG expression levels in patients 
lacking the TMPRSS2-ERG gene fusion with patients harboring the TMPRSS2-ERG gene fusion. In contrast, 
expression levels of TMPRSS2 are not different between patients with or without the gene fusion. In addition to 
determining if the gene fusion alters the expression of the 5′ or 3′ gene, this visualization can also identify addi-
tional patients that may also harbor gene fusions producing similar expression consequences.
While we have demonstrated the utility of INTEGRATE-Vis using the most prevalent TMPRSS2-ERG iso-
form, INTEGRATE-Vis automatically generates plots for all predicted gene fusion isoforms. INTEGRATE-Vis 
has been implemented with reasonable default parameters to help best interpret the functions of the gene fusion 
products. It also provided ample options to enhance user-friendliness (Figures S2 and S3). INTEGRATE-Vis 
executes efficiently; figure generation takes a few seconds (Figure S4).
Discussion
Overall, we developed the first comprehensive gene fusion visualization tool, INTEGRATE-Vis, which generates 
publication-quality graphics to help a user infer the potential consequence of a gene fusion event. We have imple-
mented INTEGRATE-Vis to utilize standardized input files, including the SMC-RNA BEDPE format for gene 
fusion predictions, therefore making it widely accessible to the larger research community independent of the 
gene fusion discovery tool being used.
Methods
The INTEGRATE-Vis pipeline was implemented in Python and C++, and requires a minimal set of dependencies 
(CMake, GCC, Matplotlib, and gtfToGenePred) to install and execute. The input into INTEGRATE-Vis includes 
a list of gene fusion candidates in a standard BEDPE format as well as other common standardized inputs (i.e. 
FASTA, GTF) including a reference genome and gene models. 333 BEDPE files can be downloaded from https://
github.com/ChrisMaherLab/INTEGRATE-Vis, including gene fusions previously discovered10. Additional input 
files in TSV format (i.e. a protein domain table and an ideogram table for cytogenetic bands) and the commands 
to generate these TSV files are all included at https://github.com/ChrisMaherLab/INTEGRATE-Vis. Read counts 
for the samples were calculated using FeatureCounts11. INTEGRATE-Vis performs a series of annotation and 
calculation steps before generating figures summarizing the gene fusion in PDF format (Fig. 1).
Availability and requirements. The INTEGRATE-Vis pipeline has been tested using Python version 2.7 
and requires CMake, GCC, Matplotlib, and gtfToGenePred to install and execute. It is available from https://
github.com/ChrisMaherLab/INTEGRATE-Vis, which also contains instructions and links for downloading 
required tools or packages, step-by-step instructions of installing INTEGRATE-Vis pipeline, and sample com-
mand lines of executing INTEGRATE-Vis from either BEDPE files or raw RNA-seq reads. Raw sequence reads of 
TCGA PRAD cohort can be downloaded from Genomic Data Commons (https://gdc.cancer.gov).
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